Microcap Ledger Phio Pharmaceuticals Corp. $PHIO
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- King Of Prussia, PA
- Fiscal year end
- December 31
- Shares outstanding
- 11,617,250 [10-Q 2026-08-06]
What the company doesAI summary of filing
Phio Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company developing cancer immunotherapy treatments using its proprietary INTASYL small interfering RNA technology. The company's INTASYL compounds are designed to silence genes that help tumors evade the immune system, with a lead candidate, PH-762, currently in a Phase 1b clinical trial for cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma. The company does not manufacture products and relies on contract manufacturers; it currently has no product revenue and is dependent on raising capital to fund its research and development activities. [10-K 2026-03-05]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$8.14M | −$8.04M | $13.00M | [10-Q 2026-08-06] |
| FY ended Dec 2025 | — | −$8.70M | −$7.98M | $21.03M | [DEF 14A 2026-08-14] |
| FY ended Dec 2024 | — | −$7.15M | −$7.11M | $5.38M | [DEF 14A 2026-08-14] |
- Quarterly cash burn
- −$4.02M
- Cash runway Estimate
- ~9.7 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-14 | 1,055,219 | [10-Q 2024-11-14] |
| 2025-03-20 | 4,778,154 | [10-K 2025-03-31] |
| 2025-05-15 | 4,798,154 | [10-Q 2025-05-15] |
| 2025-08-12 | 5,726,750 | [10-Q 2025-08-14] |
| 2025-11-11 | 10,764,428 | [10-Q 2025-11-13] |
| 2026-03-02 | 11,617,250 | [10-K 2026-03-05] |
| 2026-05-05 | 11,617,250 | [10-Q 2026-05-07] |
| 2026-08-04 | 11,617,250 | [10-Q 2026-08-06] |
- Shelf registration
- S-3 filed 2025-11-20; declared effective 2025-12-03 [S-3 2025-11-20]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-09-29 | Plott Ronald Todd | buy | 5,000 | $1.04 | [4 2026-09-30] |
| 2026-09-28 | Plott Ronald Todd | buy | 5,000 | $1.03 | [4 2026-09-30] |
| 2026-09-28 | Carson Lisa Cabott | grant | 108,000 | — | [4 2026-09-29] |
| 2026-09-28 | Bitterman Robert J | grant | 400,000 | — | [4 2026-09-29] |
| 2026-09-28 | Plott Ronald Todd | grant | 17,000 | — | [4 2026-09-29] |
| 2026-09-24 | Bradford Patricia A | buy | 6,500 | $1.01 | [4 2026-09-25] |
| 2026-09-22 | Bitterman Robert J | buy | 2,000 | $1.03 | [4 2026-09-23] |
| 2026-09-15 | Bradford Patricia A | buy | 12,000 | $1.03 | [4 2026-09-16] |
| 2026-09-11 | Carson Lisa Cabott | other | 12,888 | $1.03 | [4 2026-09-15] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-28 | 8-K | Director or officer change; Shareholder vote results |
| 2026-09-14 | 8-K | Other events |
| 2026-08-14 | DEF 14A | Proxy statement |
| 2026-08-06 | 8-K | Results of operations |
| 2026-08-06 | 10-Q | Quarterly report |
| 2026-07-21 | 8-K | Director or officer change; Other events |
| 2026-05-07 | 10-Q | Quarterly report |
| 2026-05-07 | 8-K | Results of operations |
| 2026-04-08 | 8-K | Material agreement entered |
| 2026-04-08 | 424B5 | Prospectus or prospectus supplement |
| 2026-03-30 | 8-K | Other events |
| 2026-03-05 | 10-K | Annual report |
Alerts for $PHIO
Email me when Phio Pharmaceuticals Corp. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.